13th Annual Patient Recruitment and Retention Summit

24 – 25 February 2021 | Online

PAST SPEAKERS

SEE THE PREVIOUS SPEAKERS & CASE STUDIES

Vladimir ANISIMOV

Principal Data Scientist

Sigrid ACHENBACH

Head of Clinical Trial Transparency

Lasse FUNCH JACOBSEN

Senior Lead of Patient Research and Alliances

Sotirios PERDIKEAS

Global Head Resource Management and Analytics

Domenico MERANTE

VP, Global Clinical Development

CONFERENCE TOPICS 2021

LOOK AT THE TOPICS THAT WERE DISCUSSED

  • Diversification of your patient recruitment approach
  • What is truly essential to ensure patient retention?
  • How to build the patient-centred culture across the company?
  • What are the challenges of virtual clinical trials?
  • To what extend is COVID-19 impacting clinical trial recruitment?
  • Is the impact of this pandemic on the world of clinical research uncertain for the foreseeable future?
  • How to use the technology to enhance the research?
  • Looking past COVID-19, will patients be more cautious and hesitant to participate in the future?
  • How data-driven approaches can boost the recruitment processes?

Designed for

Members of board, C-level, Senior/Global Vice Presidents, Directors, Heads of departments from the pharma industry involved in:

  • Patient Recruitment
  • Patient Retention
  • Clinical Trials
  • Clinical Study
  • Patient Centricity
  • Recruitment Programmes
  • Patient Engagement
  • Site & Patient Access
  • Trials Transparency
  • Feasibility & Recruitment
  • Patient Research

Vladimir ANISIMOV

Principal Data Scientist

CASE STUDY / DAY 1

Recent Advances in Maximising Clinical Trials Recruitment Predictability

The advanced analytics statistical methodology for modelling and forecasting patient recruitment is proposed. It allows forecasting recruitment at different levels (site/country/region) and re-projecting and optimally adjusting recruitment using interim data and Bayesian technique. The technique for optimal selecting sites/countries at the design stage to complete recruitment in time with a given confidence accounting for cost/time constraints is also presented. Further developments to forecasting event counts in event-driven trials accounting for ongoing recruitment are also discussed.

  • Modelling and forecasting recruitment at different levels
  • Optimal trial design accounting for countries/cost/time constraints
  • Data-driven interim re-projecting and optimal adjustment of recruitment
  • Forecasting event counts in event-driven trials
CASE STUDY / DAY 1

Co-Creating Win-Win Success

The success of clinical trials involves understanding what an ideal setup would look like from a participant and a regulatory perspective. The two are now practically united in guidance from EMA and FDA both. Hence, engaging disease experience experts (aka “patients”) for their advice and input is and should be an integrated part of medicines developments.

  • Disease Expert Panels at LEO Pharma
  • Co-creating with disease experts from the development phase
  • Enabling engagement beyond R&D

Lasse FUNCH JACOBSEN

Senior Lead of Patient Research and Alliances

Sotirios PERDIKEAS

Global Head Resource Management and Analytics

CASE STUDY / DAY 2

How Data-Driven Approaches Can Complement the Business Recruitment Efforts

How advanced analytics and emerging technologies can enable the business to achieve the recruitment goals? How real-world data can contribute in that direction and support the business to identify eligible patients on certain indication and geographies?

  • Machine learning for protocol feasibility
  • Predictive analytics to identify the high performing sites
  • RWD + in-house data + new data: Will they provide new insights and support the decision-making?
  • Challenges and opportunities in adopting AA techniques throughout the recruitment
CASE STUDY / DAY 2

Clinical Trial Transparency and Patient Centricity

Clinical Trial Transparency has been improved over the past years. However, in terms of patient centricity, there is still much room for improvement: Although clinical trial results have been published for quite some time, this has mostly been done using scientific language not easy to understand for patients or other laypersons. Patient centricity requires the translation of clinical trial result into a language that can be understood by a non-scientific audience. Article 37 of the EU Clinical Trial Regulation has implemented this requirement and sponsors need to set up new processes to comply.

Sigrid ACHENBACH

Head of Clinical Trial Transparency

SPONSORS

Enjoyed the event - very valuable. Good variety of topics and presentations – taking away lots of good ideas.

Head of Clinical Operations UK and Ireland at GSK

STAY UPDATED FOR THE 2022 EDITION

Provide Us With Your Contact Details and Our Team Will Get Back to You With All the Updates Regarding the Upcoming Edition of This Event.